Australia markets close in 3 hours 45 minutes

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.64-0.21 (-2.68%)
At close: 04:00PM EST
7.59 -0.05 (-0.65%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close7.85
Bid7.59 x 800
Ask7.67 x 1800
Day's range7.44 - 7.96
52-week range7.44 - 157.98
Avg. volume4,068,533
Market cap414.954M
Beta (5Y monthly)0.49
PE ratio (TTM)N/A
EPS (TTM)-4.14
Earnings date28 Feb 2022 - 04 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est56.20
  • Simply Wall St.

    We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • Motley Fool

    Why Allakos Stock Plummeted 87.5% in the Last Month of 2021

    Allakos published phase 3 Enigma 2 and phase 2/3 Kryptos trial data on its lirentelimab monoclonal antibody as a treatment for eosinophilic gastrointestinal diseases (EGIDs), and the results shocked the market. Lirentelimab had shown promising results as a treatment for eosinophilic gastrointestinal diseases in its phase 2 trials, and the phase 3 data caught the market off guard. The crushing study results were followed by a series of downgrades from high-profile analysts.

  • Zacks

    Down 86.1% in 4 Weeks, Here's Why Allakos Inc. (ALLK) Looks Ripe for a Turnaround

    Allakos Inc. (ALLK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.